Please replace the paragraph beginning at page 2, line 20, with the following rewritten paragraph:

L represents a radical of formula

-Alk-Y^1-Het^1 (c-1),

-Alk-NH-CO-Het^2 (c-2) or

-Alk-Het^3 (c-3) ; wherein

Alk represents C_{1-4}alkanediyl;

Y^1 represents O, S or NH;

Please replace the paragraph (formula) beginning at page 3, line 1, with the following rewritten paragraph:



wherein

A^1-Z^1 represents S-CH=CH, S-CH_2-CH_2, S-CH_2-CH_2-CH_2, CH=CH-CH=CH, or CH_2-CH_2-CH_2-CH_2;

In the Claims

Please cancel claims 1-8 and 10-15, without prejudice.

Please add new claims 16-30, as follows:

16. (New) A compound of formula



(I)

or a prodrug, a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein

R^1 is hydrogen, C_{1-6}alkyl, halo, formyl, carboxyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkylcarbonyl, $N(R^3R^4)C(=O)$-, $N(R^3R^4)C(=O)N(R^5)$-, ethenyl substituted with carboxyl or C_{1-6}alkyloxycarbonyl, or C_{1-6}alkyl substituted with hydroxy, carboxyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, $N(R^3R^4)C(=O)$-, C_{1-6}alkyl$C(=O)N(R^5)$-, C_{1-6}alkyl$S(=O)_2N(R^5)$- or $N(R^3R^4)C(=O)N(R^5)$-;

wherein each R^3 and each R^4 independently are hydrogen or C_{1-4}alkyl;

R^5 is hydrogen or hydroxy;

R^2 is hydrogen, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, C_{1-6}alkyloxyC_{1-6}alkyl, $N(R^3R^4)C(=O)$-, aryl or halo;

n is 1 or 2;

-A-B- represents a bivalent radical of formula

-Y-CH=CH- (a-1);

-CH=CH-Y- (a-2); or

-CH=CH-CH=CH- (a-3);

wherein each hydrogen atom in the radicals (a-1) to (a-3) may independently be replaced by R^6 wherein R^6 is selected from C_{1-6}alkyl, halo, hydroxy, C_{1-6}alkyloxy, ethenyl substituted with carboxyl or C_{1-6}alkyloxycarbonyl, hydroxyC_{1-6}alkyl, formyl, carboxyl or hydroxycarbonylC_{1-6}alkyl;

each Y independently is a bivalent radical of formula -O-, -S- or -NR^7-;

wherein R^7 is hydrogen, C_{1-6}alkyl or C_{1-6}alkylcarbonyl;

Z is a bivalent radical of formula

-$(CH_2)_p$- (b-1),

-CH=CH- (b-2),

-CH_2-CHOH- (b-3),

-CH_2-O- (b-4),

-CH_2-C(=O)- (b-5), or

-CH_2-C(=NOH)- (b-6),

with the proviso that the bivalent radicals (b-3), (b-4), (b-5) and (b-6) are connected to the nitrogen of the imidazole ring via their -CH_2- moiety;

wherein p is 1, 2, 3 or 4;

L is hydrogen; C_{1-6}alkyl; C_{2-6}alkenyl; C_{1-6}alkylcarbonyl; C_{1-6}alkyloxycarbonyl; C_{1-6}alkyl substituted with one or more substituents each independently selected from hydroxy, carboxyl, C_{1-6}alkyloxy, C_{1-6}alkyloxycarbonyl, aryl, aryloxy, cyano or R^8HN- wherein R^8 is hydrogen, C_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, or C_{1-6}alkylcarbonyl; or

L represents a radical of formula

-Alk-Y^1-Het^1 (c-1),

-Alk-NH-CO-Het^2 (c-2) or

-Alk-Het^3 (c-3) ; wherein

Alk represents C_{1-4}alkanediyl;

Y^1 represents O, S or NH;

Het^1 and Het^2 each represent furanyl, tetrahydrofuranyl, thienyl, oxazolyl, thiazolyl or imidazolyl each optionally substituted with one or two C_{1-4}alkyl substituents; pyrrolyl or pyrazolyl optionally substituted with formyl, hydroxyC_{1-4}alkyl, hydroxycarbonyl, C_{1-4}alkyloxy-carbonyl or with one or two C_{1-4}alkyl substituents; thiadiazolyl or oxadiazolyl optionally substituted with amino or C_{1-4}alkyl; pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl each optionally substituted with C_{1-4}alkyl, C_{1-4}alkyloxy, amino, hydroxy or halo; and

Het^3 represents furanyl, tetrahydrofuranyl, thienyl, oxazolyl, thiazolyl or imidazolyl each optionally substituted with one or two C_{1-4}alkyl substituents; pyrrolyl or pyrazolyl optionally substituted with formyl, hydroxyC_{1-4}alkyl, hydroxycarbonyl, C_{1-4}alkyloxycarbonyl or with one or two C_{1-4}alkyl substituents; thiadiazolyl or oxadiazolyl optionally substituted with amino or C_{1-4}alkyl; pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl each optionally substituted with C_{1-4}alkyl, C_{1-4}alkyloxy, amino, hydroxy, halo, 4,5-dihydro-5-oxo-1H-tetrazolyl substituted with C_{1-4}alkyl, 2-oxo-3-oxazolidinyl, 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl or a radical of formula



wherein

A^1-Z^1 represents S-CH=CH, S-CH_2-CH_2, S-CH_2-CH_2-CH_2, CH=CH-CH=CH, or CH_2-CH_2-CH_2-CH_2;

aryl is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, C_{1-4}alkyl, polyhaloC_{1-4}alkyl, cyano, aminocarbonyl, C_{1-4}alkyloxy or polyhaloC_{1-4}alkyloxy;

with the proviso that 5,6-dihydrospiro[imidazo[1,2-b][3]benzazepine-11[11H],4'-piperidine] and pharmaceutically acceptable addition salts thereof are not included.

C' cont

17. (New) A compound according to claim 16 wherein L is hydrogen, C_{1-6}alkyl, C_{1-6}alkylcarbonyl, C_{1-6}alkyloxycarbonyl or C_{1-6}alkyl substituted with hydroxy, carboxyl, C_{1-6}alkyloxy or C_{1-6}alkyloxycarbonyl.

B4

18. (New) A compound according to claim 16 wherein L is C_{1-6}alkyl substituted with aryl and C_{1-6}alkyloxycarbonyl.

19. (New) A compound according to claim 16 wherein -A-B- is a bivalent radical of formula -CH=CH-CH=CH- (a-3) or –CH=CH-Y- (a-2).

20. (New) A compound according to claim 16 wherein Z is $-(CH_2)_p-$ (b-1), -CH=CH- (b-2), or $-CH_2-O-$ (b-4).

21. (New) A compound according to claim 16, wherein L is hydrogen, C_{1-6}alkyl, hydroxyC_{1-6}alkyl, carboxyC_{1-6}alkyl, C_{1-6}alkyloxycarbonyl, or C_{1-6}alkyloxycarbonylC_{1-6}alkyl.

22. (New) A compound according to claim 16 wherein R^1 is hydroxyC_{1-6}alkyl, formyl, C_{1-6}alkyloxycarbonyl, C_{1-6}alkyloxyC_{1-6}alkyl, $N(R^3R^4)C(=O)-$, halo or hydrogen.

23. (New) A compound according to claim 16 wherein the compound is 5,6-dihydrospiro[11H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide

B

dihydrochloride;

1'-butyl-5,6-dihydrospiro[imidazo[2,1-b] [3] benzazepine-11-[11H],4'-piperidine];

6,11-dihydro-1'-methylspiro[5H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] cyclohexylsulfamate(1:2);

6,11-dihydrospiro[5-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-methanol (E)-2-butenedioate (2:1);

3-chloro-6,11-dihydrospiro[5H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (E)-2-butenedioate (1:1);

11-dihydro-3-(methoxymethyl)spiro[5H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine] (E)-2-butenedioate (1:1);

6,11-dihydro-1'-(2-hydroxyethyl)spiro[5H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide;

6,11-dihydro-1'-methylspiro[5H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-3-carboxamide monohydrate;

ethyl 3-(aminocarbonyl)-6,11-dihydro-α-phenylspiro[5H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-1'-propanoate monohydrochloride;

3-(aminocarbonyl)-6,11-dihydrospiro[5H-imidazo[2,1-b][3]-benzazepine-11,4'-piperidine]-1'-carboxylate;

spiro[10H-imidazo[1,2-a]thieno[3,2-d]azepine-10,4'-piperidine];

6,11-dihydrospiro[5H-imidazo[2,1-b][3]benzazepine-11,4'-piperidine]-2,3-dicarboxamide dihydrochloride monohydrate; or

a prodrug, a N-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof.

24. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as defined in claim 16.

25. (New) A process of preparing a pharmaceutical composition, wherein a pharmaceutically acceptable carrier is mixed with a therapeutically effective amount of a compound as defined in claim 16.

26. (New) A compound of formula



(II-a)

or a *N*-oxide, an addition salt, a quaternary amine or a stereochemically isomeric form thereof wherein P is a protective group and n, -A-B-, Z, R^1 and R^2 are defined as in claim 16, with the proviso that 6,11-dihydro-1'-(phenylmethyl)-5*H*-spiro[imidazo[1,2-b][3]-benzazepine-11,4'-piperidine] (E)-2-butenedioate(1:2) is not included .

27. (New) A compound according to claim 26 wherein P is benzyl.

28. (New) A process of preparing a compound as claimed in claim 16, comprising

a) deprotecting an intermediate of formula (II), followed optionally by derivatizing either the piperidine moiety, or the imidazole moiety, or both the piperidine moiety and the imidazole moiety



(II) (I)

with P being a protective group;

b) derivatizing an intermediate of formula (II) at the imidazole moiety, to form an intermediate of formula (II-a), followed by deprotecting the piperidine moiety, and followed optionally by derivatizing the piperidine moiety



(II) (II-a) (I)

c) cyclizing an intermediate of formula (III) in the presence of an appropriate acid, to form a compound of formula (I-a)



C1 Cont

and, optionally, converting compounds of formula (I) and (I-a) into each other, and further, optionally, converting the compounds of formula (I), into a therapeutically active non-toxic acid addition salt by treatment with an acid, or into a therapeutically active non-toxic base addition salt by treatment with a base, or converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, optionally, preparing stereochemically isomeric forms or N-oxide forms thereof.

B4

29. (New) A process of preparing a compound as claimed in claim 27, comprising,

a) cyclizing a compound of formula (XI) with an appropriate acid, to form a compound of formula (II-k), followed optionally by derivatizing the imidazole moiety, to form a compound of formula (II-a-1)



B

with Z_1 being a bivalent radical of formula $-(CH_2)_p-$, wherein p is 1,2,3 or 4; and

b) reacting a tricyclic moiety of formula (XIV) with a reagent of formula (XV) under an inert atmosphere in a reaction inert solvent in the presence of a suitable base, to form a compound of formula (II-l), followed optionally by derivatizing the imidazole moiety to form a compound of formula (II-a-2)



(XIV) (XV) (II-l) (II-a-2)

with W_5 being a suitable leaving group, and Z_2 being a bivalent radical of formula $-(CH_2)_p-$, or $-CH_2-O-$, wherein p is 1,2,3 or 4.

30. (New) A method of treating a subject suffering from allergic disease, comprising administering to said subject a therapeutically effective amount of a compound as defined in claim 16.

REMARKS

Claims 16-30 are presented. Claims 1-8 and 10-15 have been canceled. Claims 16-29 correspond to canceled claims 1-8 and 10-15 and claim 30 finds support in the Specification at, for example, page 26, lines 31-34. Pursuant to the Examiner's request, Applicants have re-written the claims using double-spaced lines. The new claims incorporate the amendments made in connection with the Preliminary Amendment, dated June 19, 2001.